Results 101 to 110 of about 264,257 (370)

C-MYC rearrangements are frequent in aggressive mature B-cell lymphoma with atypical morphology [PDF]

, 2008
Diagnosis and classification of aggressive mature B-cell lymphoma with atypical morphology remains a challenge. To identify factors that may contribute to the atypical morphology, we selected eight such cases and evaluated their morphologic ...
Dehner, Louis P, Hassan, Anjum, Ning, Yi, Perry, Arie, Strass, Sanford A, Xianfeng, Zhao F   +5 more
core   +2 more sources

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha, A Chanan-Khan, A Davies, A Prica, AR Rezvani, B Bonavida, B Coiffier, B Coiffier, B Coiffier, B Eichhorst, B Eichhorst, BS Kahl, C Dartigeas, C Gisselbrecht, C Müller, C Taverna, CS Tam, D Daydé, D Müller, D Rossi, David G. Maloney, DG Maloney, DG Maloney, DG Maloney, DW Scott, E Bachy, E Deconinck, E Hoster, E Kimby, E Vellenga, E Zucca, EA Chong, EJ Soini, FB Hagemeister, FT Awan, G Köhler, G Lenz, G Martinelli, G Poeta Del, G Poeta Del, G Salles, G Salles, GA Salles, Gilles Salles, GJ Weiner, GJ Weiner, H Blasco, H Hochster, H Schulz, H Tilly, HC Kluin-Nelemans, HM Blommestein, HR Junlén, International CLL-IPI Working Group, J Banchereau, J Hiraga, J Hornberger, J Hornberger, J Li, JA Ray, JA Woyach, JC Byrd, JC Byrd, JM Foran, JM Vose, JO Armitage, Joerg Maurer, JP Leonard, K Fischer, K Fischer, K Fischer, K Tobinai, K Tobinai, KA Foon, KA Foon, KM Ardeshna, KM Johnston, L Li, L Tran, L Vidal, LA Torre, LD Piro, LM Nadler, M Adena, M Dreyling, M Dreyling, M Federico, M Feuring-Buske, M Hallek, M Hallek, M Herold, M Jermann, M Pfreundschuh, M Pfreundschuh, M Pfreundschuh, M Tout, MA Dimopoulos, MA Lopez-Olivo, Martin Barrett, MB Regazzi, MD Danese, ME Reff, ME Williams, MH Oers van, MH Oers van, Michael Wenger, MJ Keating, MJ Rummel, MS Czuczman, MS Czuczman, Nancy Valente, NL Berinstein, O Mandrik, OW Press, P Abrisqueta, P Boffetta, P Boross, P Colombat, P Feugier, P Hillmen, P McLaughlin, P Thompson, PV Beum, Q Chen, Q Chen, R Forstpointner, R Forstpointner, R Foà, R Griffiths, R Marcus, R Marcus, RA Miller, RI Griffiths, RI Griffiths, RL Elstrom, Robin Foà, S Assouline, S Cang, S Khor, S Maury, SG Fisher, SM Jaglowski, SM O’Brien, Susan O’Brien, T Igarashi, T Kewalramani, T Robak, TA Davis, TA Davis, TJ Kipps, TM Habermann, U Jaeger, U Jäger, UJ Mey, V Goede, V Ivanov, V Minard-Colin, V Ribrag, W Hiddemann, W Wierda, XC Badoux, Y Oki   +161 more
core   +2 more sources

WDR5‐H3K4me3 Epigenetic Axis Promotes TRMT6‐Dependent tRNA M1A Modification to Facilitate Triple‐Negative Breast Cancer Progression by Suppressing Ferroptosis

Advanced Science, EarlyView.
Upregulated TRMT6 forms aberrant hypermethylation of a specific tRNA pool and serves as a predictor of poor prognosis in TNBC. This m1A modification in tRNAs enhances translation of FTH1 and FTL, reducing the pool of bioavailable Fe2⁺. Reduced Fe2+ availability impairs RSL3‐induced lipid peroxidation and tumor progression.
Yuqing Lei, Xue Wang, Jiahe Liu, Zixu Niu, Jiaqi Hua, Qian Guo, Dan Du, Yuanchang Zhu, Fucheng He, Mingxia Zhou, Hongle Li, Jing He, Jun Li   +12 more
wiley   +1 more source

The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection

Haematologica, 2015
Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large B-cell lymphoma. Deregulation of signaling pathways involved in normal marginal zone development (NOTCH pathway, NF-κB ...
Luca Arcaini, Davide Rossi, Marco Lucioni, Marta Nicola, Alessio Bruscaggin, Valeria Fiaccadori, Roberta Riboni, Antonio Ramponi, Virginia V. Ferretti, Stefania Cresta, Gloria Margiotta Casaluci, Maurizio Bonfichi, Manuel Gotti, Michele Merli, Aldo Maffi, Mariarosa Arra, Marzia Varettoni, Sara Rattotti, Lucia Morello, Maria Luisa Guerrera, Roberta Sciarra, Gianluca Gaidano, Mario Cazzola, Marco Paulli   +23 more
doaj   +1 more source

Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development [PDF]

, 2004
Idiotypic (Id) vaccination has shown promising results in patients with follicular lymphoma (FL). However, it still remains unclear whether the same approach might be suitable for the treatment of other B-cell malignancies.
Bendandi, M. (Maurizio), Inoges, S. (Susana), Lopez-Diaz-de-Cerio, A. (Ascensión), Rodriguez-Calvillo, M. (Mercedes), Villanueva, H. (Helena), Zabalegui, N. (Natalia)   +5 more
core   +1 more source

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology, 2019
PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options.
L. Sehn, A. Herrera, C. Flowers, M. Kamdar, A. McMillan, M. Hertzberg, S. Assouline, T. Kim, W. Kim, M. Ozcan, J. Hirata, E. Penuel, J. Paulson, Ji Cheng, G. Ku, M. Matasar   +15 more
semanticscholar   +1 more source

Treatment of Diffuse Large B-Cell Lymphoma

Journal of Clinical and Experimental Hematopathology, 2016
Diffuse large B-cell lymphoma (DLBCL) comprises a heterogeneous group with pathophysiological, genetic and clinical features. Many patients can be cured with R-CHOP therapy, which is the current standard regimen. Despite recent progress in improving patient survival, the 40% survival of DLBCL patients remains poor.
openaire   +3 more sources

Functional, Pharmacogenomic, and Immune Landscapes of Long Non‐Coding RNAs in Cancer

Advanced Science, EarlyView.
A systematic analysis of 33 cancer types reveals widespread associations between lncRNAs and cancer pathways, drug responses, immune features, and immunotherapy outcomes. The study identifies key lncRNAs linked to therapeutic response and adverse events and introduces PILNC, an interactive web portal for exploring the functional, pharmacogenomic, and ...
Runhao Wang, Mei Luo, Yuan Liu, Jingwen Yang, Yamei Chen, Chengxuan Chen, Lifei Ma, Stephanie Ding, James Wengler, Yong Zang, Bora Lim, Wenbo Li, Liuqing Yang, Chunru Lin, Lixia Diao, Leng Han   +15 more
wiley   +1 more source

Early Detection of Chemotherapy‐Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium (2H) Metabolic Imaging: in Vitro and in Vivo Assessments

Advanced Science, EarlyView.
This study presents the first application of deuterium metabolic imaging (DMI) for assessing therapeutic response in bladder cancer. Employing [2,3,4,6,6′‐2H5]‐D‐glucose, DMI successfully identified chemotherapy‐induced suppression of glycolysis both in vitro and in vivo.
Lingmin Kong, Ganghan Yang, Bei Weng, Zhihua Wen, Joshua D. Kaggie, Qian Cai, Qian Wan, Cuien Zheng, Feng Du, Ye Li, Xin Liu, Ferdia A. Gallagher, Yan Guo, Shi‐Ting Feng, Chao Zou, Huanjun Wang   +15 more
wiley   +1 more source

Central nervous system lymphomas: a histologic and immunophenotypic analysis [PDF]

, 2000
Objective: To observe the spectrum of non-Hodkin’s lymphomas involving the central nervous system including morphological subtypes and immunophenotypic status.
lmran Siddiqui, lmran Siddiqui, Muzaffar, Suhail, Naila Kayani, Naila Kayani, Pervez, Shahid, Sheema H. Hasan, Sheema H. Hasan Sheema H. Hasan, Siddiqui, M. Shahid, Soomro, Irshad Nabi   +6 more
core   +1 more source